Form 4: Neurocrine Biosciences Executive Sells Shares
Statement of Changes in Beneficial Ownership
Chief Corporate Affairs Officer David W. Boyer sold 3,888 shares of Neurocrine Biosciences common stock via a 10b5-1 plan.
Summary
- David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, sold 3,888 shares of common stock.
- The transaction occurred on May 26, 2026, at a weighted average price of $156.6418 per share.
- The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on February 23, 2026.
- Following the transaction, the reporting person retains beneficial ownership of 7,799 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 arrangement, which is a standard administrative procedure for executives.
Positives
- The sale was conducted under a pre-established Rule 10b5-1 trading plan, indicating the transaction was planned in advance rather than based on non-public information.
Negatives
- The transaction represents a reduction in the insider's direct equity stake in the company.
Risks
- Insider selling can sometimes be perceived by the market as a lack of confidence in future share price appreciation, though this was a planned sale.
Future Outlook
No specific forward-looking guidance regarding company performance was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for corporate executives to manage personal liquidity and is generally viewed as neutral by the market.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for executives to avoid potential conflicts of interest regarding insider trading regulations.
Stakeholder Impact
- Minimal impact expected as the sale was pre-planned and represents a small portion of the executive's holdings.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 2026-02-23 | Date the Rule 10b5-1 trading plan was adopted. |
| 2026-02-27 | Date of purchase of 106 shares via Employee Stock Purchase Plan. |
| 2026-05-26 | Date of the reported stock sale transaction. |
| 2026-05-28 | Date the Form 4 was filed with the SEC. |
Keywords
NBIX, Neurocrine Biosciences, Insider Trading, Form 4, Stock Sale, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.